Back to Search
LINDA DRESSLER, MD
MD
Ophthalmology Physician
NPI: 1801863071IndividualAccepts Medicare
Specialties, Licenses & Credentials
Ophthalmology PhysicianPrimary
Ophthalmology
Code: 207W00000X
0101039520(VA)
CMS Specialties
PrimaryOPHTHALMOLOGY
Education
HARVARD MEDICAL SCHOOL
Class of 1982
Research & Publications (20)
Adjuvant chemotherapy in older women with early-stage breast cancer.
PMID 19439741·N Engl J Med·2009
4-observational
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
PMID 19470942·J Clin Oncol·2009
8-other
Disclosure of research results from cancer genomic studies: state of the science.
PMID 19549775·Clin Cancer Res·2009
6-review
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
PMID 18390970·J Clin Oncol·2008
2-rct
HER2 and response to paclitaxel in node-positive breast cancer.
PMID 17928597·N Engl J Med·2007
4-observational
Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease.
PMID 17070803·Exp Neurol·2007
7-preclinical
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
PMID 16757721·JAMA·2006
8-other
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
PMID 17129383·Breast Cancer Res·2006
2-rct
Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
PMID 16942640·Clin Breast Cancer·2006
3-trial
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
PMID 16773437·Breast Cancer Res Treat·2006
2-rct
The molecular portraits of breast tumors are conserved across microarray platforms.
PMID 16643655·BMC Genomics·2006
8-other
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
PMID 15994142·J Clin Oncol·2005
4-observational
High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype.
PMID 15861214·Mod Pathol·2005
8-other
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.
PMID 15144956·Cancer Cell·2004
4-observational
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
PMID 15328174·Clin Cancer Res·2004
8-other
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
PMID 15564794·Breast Cancer Res Treat·2004
8-other
HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.
PMID 12846420·Breast Cancer Res Treat·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3930 PENDER DR, SUITE 10
FAIRFAX, VA 22030 - Phone
- (703) 273-2398
Quick Facts
- NPI
- 1801863071
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 44
- Publications
- 20
Are you this provider?
Claim Your Profile